GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: Neulasta®
                                 pegfilgrastim is an approved drug (FDA and EMA (2002)) Compound class: 
                                                            Peptide
                                 
                                    
                                        Comment: This is a PEGylated version of recombinant human G-CSF. Pegylation increases circulating half-life. In addition to pegfilgrastim, lipegfilgrastim (Lonquex®) is a glyco-PEGylated long-acting G-CSF, that is an alternative to pegfilgrastim [1].  Biosimilars: 
 | 
| Classification  | |
| Compound class | Peptide | 
| Approved drug? | Yes. EU EMA (2002) | US FDA (2002) | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 8114 | pegfilgrastim | 
| Synonyms  | 
| Neulasta® | 
| Database Links  | |
| Specialist databases | |
| IMGT/mAb-DB | 616 | 
| Other databases | |
| CAS Registry No. | 208265-92-3 (source: Scifinder) | 
| ChEMBL Ligand | CHEMBL1201568 | 
| DrugBank Ligand | DB00019 | 
| GtoPdb PubChem SID | 178103549 | 
| Search PubMed clinical trials | pegfilgrastim | 
| Search PubMed titles | pegfilgrastim | 
| Search PubMed titles/abstracts | pegfilgrastim | 
| Wikipedia | Pegfilgrastim |